Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZIO-101 · 3 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZIO-101 (Darinaparsin) | DRUG | IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months |
Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ZIO-101 is an investigational small molecule being studied for the treatment of acute leukemia, multiple myeloma, and solid tumors. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is being developed by Alaunos Therapeutics, Inc. (NASDAQ: TCRT).
ZIO-101 is a small molecule, but its specific molecular target has not been disclosed. It is being investigated for its potential anti-cancer activity in hematologic malignancies and solid tumors, though the exact mechanism of action is not publicly detailed.
ZIO-101 is being developed by Alaunos Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol TCRT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with various cancers.
ZIO-101 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. All three clinical trials for ZIO-101 have been completed, and the drug is no longer in active testing.
ZIO-101 has completed three Phase 1 trials: NCT00303199 in multiple myeloma (35 patients), NCT00591396 in solid tumors (40 patients), and NCT00592046 in hematologic cancers including acute leukemia and multiple myeloma (12 patients). All trials are completed and were uncontrolled, non-randomized studies.
ZIO-101 is the primary name for this investigational compound. No alternative names have been reported in clinical trial registrations. It is a distinct small molecule being developed by Alaunos Therapeutics for oncology indications.